Redmile Group, LLC's Form 4 filing
Attovia Therapeutics, Inc. (ATTO) · filed Aug 7, 2026
- Accession no.
- 0001104659-26-092867
- Filed
- Aug 7, 2026, 9:47 PM ET
- Trade date
- Aug 6, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market purchases total $10.2M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Redmile Group, LLCCIK 0001425738 | 10% Owner |
| Green JeremyCIK 0001650527 | 10% Owner |
| Redmile Biopharma Investments III, L.P.CIK 0001838746 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | Common Stock | CConversionAcquired | +782,854 | –F1 | – | 782,854 | Indirect | |
| Aug 6, 2026 | Common Stock | PPurchaseAcquired | +200,000 | $17.00 | +$3,400,000 | 982,854 | Direct | |
| Aug 6, 2026 | Common Stock | PPurchaseAcquired | +400,000 | $17.00 | +$6,800,000 | 1,182,854 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | Common Stock | CConversionDisposed | −782,854 | –F1 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On August 6, 2026, the Series B Preferred Stock converted by its terms in full automatically into shares of the Issuer's common stock, upon the consummation of the Issuer's initial public offering ("IPO"), for no consideration. The Series B Preferred Stock had no expiration date.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.